The views expressed here are those of the individual authors and not necessarily those of the JSM sponsors, their officers, or their staff.
Abstract Details
Activity Number:
|
423
|
Type:
|
Contributed
|
Date/Time:
|
Tuesday, August 2, 2011 : 2:00 PM to 3:50 PM
|
Sponsor:
|
Biopharmaceutical Section
|
Abstract - #301596 |
Title:
|
Using Z-Prime Factor as Quantitative Measure of In Vivo PD Assay Quality
|
Author(s):
|
Winnie Weng*+ and Guang Chen and Margaret Weidner and Kathy Keegan and Christophe Queva
|
Companies:
|
Amgen Inc. and Amgen Inc. and Amgen Inc. and Amgen Inc. and Amgen Inc.
|
Address:
|
1201 Amgen CT W, Seattle, WA, 98119,
|
Keywords:
|
z prime factor ;
PD assay ;
pharmacodynamic assay ;
in vivo
|
Abstract:
|
In vivo pharmacodynamic (PD) assays have been used extensively in preclinical studies of drug development. They are used to develop a correlation between the mechanism of action of a drug with its desired efficacious outcome. To date, in vivo screening assays are evaluated independently without a standard method to compare one to another. Here we present the development of Z prime factor; a simple statistical parameter reflecting the combined effect of width of the assay window (i.e. difference between positive and negative controls), variation associated with assay, and number of animal and/or technical replicates used. Using Z prime factor as a quantitative measure of in vivo PD Assay quality, investigators can determine if the assay is sensitive enough for drug compound screening, as well as to estimate the fewest number of animals needed to achieve statistically significance, and to compare quality of different assay platforms.
|
The address information is for the authors that have a + after their name.
Authors who are presenting talks have a * after their name.
Back to the full JSM 2011 program
|
2011 JSM Online Program Home
For information, contact jsm@amstat.org or phone (888) 231-3473.
If you have questions about the Continuing Education program, please contact the Education Department.